Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (81-90 of 387) with videos related to

Pageof 39
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|November 6, 2007
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphomaChristos Emmanouilides, Thomas E Witzig, Gregory A Wiseman, et al.
Haematologica|October 10, 2024
CODOX-M/IVAC-R <i>versus</i> DA-EPOCH-R in double-hit/triple-hit lymphoma patients aged 60 years or underSuheil Albert Atallah-Yunes, Matthew J Rees, Thomas E Witzig, et al.
Leukemia & Lymphoma|May 13, 2006
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphomaChristos Emmanouilides, Thomas E Witzig, Leo I Gordon, et al.
Blood|March 27, 2009
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activationMamta Gupta, Stacey R Dillon, Steven C Ziesmer, et al.
Blood Cancer Journal|January 6, 2022
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trialsYucai Wang, Shouhao Zhou, Xinyue Qi, et al.
The American Journal of Gastroenterology|October 10, 2006
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancersFrank A Sinicrope, Rafaela L Rego, Nathan Foster, et al.
Nutrition and Cancer|September 21, 2018
Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?Gita Thanarajasingam, Matthew J Maurer, Thomas M Habermann, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 4, 2021
Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexateJason N Barreto, Kristen T Peterson, Erin F Barreto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) studyAndre Goy, Rajni Sinha, Michael E Williams, et al.
The Oncologist|October 17, 2024
Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphomaJennifer J Gile, Matthew Maurer, Gordon J Ruan, et al.
Pageof 39

Showing results (81-90 of 387) with videos related to

Sort By:
Pageof 39
Cancer Biotherapy & Radiopharmaceuticals|November 6, 2007
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphomaChristos Emmanouilides, Thomas E Witzig, Gregory A Wiseman, et al.
Haematologica|October 10, 2024
CODOX-M/IVAC-R <i>versus</i> DA-EPOCH-R in double-hit/triple-hit lymphoma patients aged 60 years or underSuheil Albert Atallah-Yunes, Matthew J Rees, Thomas E Witzig, et al.
Leukemia & Lymphoma|May 13, 2006
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphomaChristos Emmanouilides, Thomas E Witzig, Leo I Gordon, et al.
Blood|March 27, 2009
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activationMamta Gupta, Stacey R Dillon, Steven C Ziesmer, et al.
Blood Cancer Journal|January 6, 2022
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trialsYucai Wang, Shouhao Zhou, Xinyue Qi, et al.
The American Journal of Gastroenterology|October 10, 2006
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancersFrank A Sinicrope, Rafaela L Rego, Nathan Foster, et al.
Nutrition and Cancer|September 21, 2018
Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?Gita Thanarajasingam, Matthew J Maurer, Thomas M Habermann, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 4, 2021
Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexateJason N Barreto, Kristen T Peterson, Erin F Barreto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) studyAndre Goy, Rajni Sinha, Michael E Williams, et al.
The Oncologist|October 17, 2024
Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphomaJennifer J Gile, Matthew Maurer, Gordon J Ruan, et al.
Pageof 39